Medical gadget maker Medtronic plc (NYSE: MDT) on Tuesday reported greater revenues and adjusted earnings for the second quarter of fiscal 2026. The numbers topped analysts’ expectations.
Second-quarter earnings, excluding one-off objects, rose to $1.36 per share from $1.26 per share within the year-ago interval. On a reported foundation, web revenue was $1.37 billion or $1.07 per share in Q2.
Complete revenues elevated to $8.96 billion within the second quarter from $8.40 billion in Q2 2025. Revenues of the Cardiovascular and Neuroscience segments elevated by 9.3% and three.9% respectively.
Geoff Martha, Medtronic’s CEO, stated, “Looking ahead, we are positioned for even greater acceleration of revenue growth in the back half of the year and beyond, driven by several enterprise growth drivers, including our PFA franchise for Afib, Symplicity procedure for hypertension, Hugo robotic-assisted surgery system, and Altaviva therapy for urge urinary incontinence.”
For fiscal 2026, the corporate expects natural income development of roughly 5.5%. The steering for full-year adjusted earnings per share is within the vary of $5.62 to $5.66.
